2X Blend – 16mg (Tesamorelin & Ipamorelin)
Certificates of Analysis
This 2X Blend supplies two growth hormone secretagogues in a single vial: Tesamorelin at 13 mg and Ipamorelin at 3 mg. The two peptides are chemically distinct and act at different receptors, which is the reason they are studied as a pair rather than as interchangeable compounds.
Tesamorelin is a stabilized analog of growth hormone-releasing hormone and binds the GHRH receptor on pituitary somatotrophs. Ipamorelin is a selective agonist of the growth hormone secretagogue receptor GHS-R1a, the ghrelin receptor. Published work describes the two receptors as converging on somatotroph secretion through different second-messenger routes, and describes ipamorelin as selective in the specific sense that it did not meaningfully raise cortisol or prolactin in the reported experiments. That selectivity was established for ipamorelin alone.
The available literature covers each peptide separately. Published work on tesamorelin as a single agent has examined visceral adipose tissue and IGF-1 measures; those results belong to that single-agent context and were not generated with ipamorelin present. No combination-specific potency, ratio optimum or interaction value is stated for this pairing, and study designs using it generally retain single-agent control arms.
Supplied in a single vial for laboratory reconstitution and handling by qualified personnel. This product is intended for laboratory research use only. It is not a drug, is not for human or veterinary use, and is not for diagnostic or therapeutic application.
Couldn't load pickup availability
Need reconstitution solution? Don’t forget to add Bacteriostatic Water before checkout.
Dual-Receptor Secretagogue Blend
Two Peptides Acting on Two Distinct Receptors of the Same Axis
This 2X Blend supplies Tesamorelin and Ipamorelin in a single vial, at 13 mg and 3 mg respectively. Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH) and binds the GHRH receptor expressed on pituitary somatotrophs. Ipamorelin is a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), the receptor for ghrelin. The two compounds therefore engage different receptors expressed on the same pituitary cell population. Laboratories select a fixed-ratio preparation of this kind when a protocol calls for both receptor signals to be present in one reconstituted solution rather than in two separately handled vials. Each constituent carries its own published literature, and the sections below describe the pairing using what is established for each constituent separately.
Receptor Signalling & Selectivity
How Tesamorelin and Ipamorelin Reach the Somatotroph by Different Routes
The two receptors engaged here are distinct proteins with distinct endogenous ligands. Tesamorelin acts at the GHRH receptor, the pituitary target of hypothalamic growth hormone-releasing hormone. Ipamorelin acts at GHS-R1a, the ghrelin receptor. Published work describes the two as converging on somatotroph secretion through different second-messenger routes, which is why investigators treat them as separable inputs rather than as a single pathway.
Ipamorelin is described in published work as a selective GHS-R1a agonist, in the specific sense that it did not meaningfully raise cortisol or prolactin in the reported experiments. That selectivity profile is a property established for ipamorelin alone. It has not been demonstrated for this blend and should not be read as describing the combination.
Research Applications
From Single-Agent Endocrine Studies to Combination Study Design
Published work on Tesamorelin as a single agent has examined visceral adipose tissue and IGF-1 measures. Those measures were reported in that single-agent context; they were not generated with ipamorelin present, and they do not transfer to this blend by implication.
The more direct use for a fixed-ratio preparation is study design work on peptide combinations: how two receptor agonists supplied in one solution are handled, sequenced and controlled for, and how an experiment can attribute an observed change to one constituent, the other, or their co-presence. Designs of this kind generally retain single-agent arms alongside the blend. Published work specific to this pairing is limited, and no combination-specific potency, efficacy or synergy figure is stated here.
The Science Behind Dual-Receptor Secretagogue Research: Why Tesamorelin and Ipamorelin Are Studied Together
The somatotropic axis is regulated at the pituitary by more than one receptor. Tesamorelin acts at the GHRH receptor, the pituitary target of hypothalamic growth hormone-releasing hormone, and is a stabilized analog of that hormone. Ipamorelin acts at GHS-R1a, the ghrelin receptor, a separate receptor with its own endogenous ligand and its own signalling cascade.
The rationale for studying them in one preparation is mechanistic rather than empirical: two agonists with distinct receptors and distinct second-messenger routes converge on the same somatotroph population, which makes the pairing a model for questions about convergent endocrine signalling. That is a reason to run an experiment, not a result of one.
Investigators should note the limits of what can be stated. Each peptide has been characterized individually in its own published literature, as a single agent. The pairing is not characterized here as a single entity, so no combined potency, ratio optimum or interaction figure is given, and none should be inferred. Any such value would have to come from the investigator's own controlled arms.
Scientific Literature
- Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs. 2009;18(3):303-10.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.
- Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6.
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-6.
Packaged with care, shipped fast.
We’re a passionate team obsessed with quality, not margins.
- Company
- Price
- Purity
- Quantity
- Shipping
-
TB-500 – 5mg
-
Prime
Lab PeptidesTypical
Competitor -
$45.00$80.00
- ≥99%97%
- 5mg5mg
- Free 2-Day Shipping3-10 Business Day
-
